Journal of the Neurological Sciences
Volume 213, Issue 1 , Pages 61-65 , 15 September 2003

Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients

Received 12 September 2002 ,Revised 5 May 2003 ,Accepted 8 May 2003.

References 

  1. Bodis-Wollner I, Yahr MD. Measurements of visual evoked potentials in Parkinson's disease. Brain. 1978;101(4):661–671
  2. Stanzione P, Fattapposta F, Tagliati M, D'Alessio C, Marciani MG, Foti A, et al.  Dopaminergic pharmacological manipulations in normal humans confirm the specificity of the visual (PERG-VEP) and cognitive (P300) electrophysiological alterations in Parkinson's disease. Electroencephalogr. Clin. Neurophysiol. 1990;41:216–220 (Suppl.)
  3. Bodis-Wollner I, Tagliati M. The visual system in Parkinson's disease. Adv. Neurol. 1993;60:390–394
  4. Harris J. Vision in Parkinson's disease: what are the deficits and what are their origins?. Neuro. Ophthalmol. 1998;19:113–135
  5. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest. Ophthalmol. Vis. Sci. 1990;31(11):2473–2475
  6. Kinnear PR. Proposals for scoring and assessing the 100-Hue test. Vision Res. 1970;10(5):423–433
  7. Pieri V, Diederich NJ, Raman R, Goetz CG. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J. Neurol. Sci. 2000;172(1):7–11
  8. Büttner T, Kuhn W, Müller T, Patzold T, Heidbrink K, Przuntek H. Distorted color discrimination in ‘de novo’ parkinsonian patients. Neurology. 1995;45(2):386–387
  9. Müller T, Kuhn W, Buttner T, Przuntek H. Colour vision abnormalities and movement time in Parkinson's disease. Eur. J. Neurol. 1999;6(6):711–715
  10. Müller T, Kuhn W, Buttner T, Eising E, Coenen H, Haas M, et al.  Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease. J. Neurol. 1998;245(10):659–664
  11. Müller T, Kuhn W, Buttner T, Przuntek H. Distorted colour discrimination in Parkinson's disease is related to severity of the disease. Acta Neurol. Scand. 1997;96(5):293–296
  12. Regan BC, Freudenthaler N, Kolle R, Mollon JD, Paulus W. Colour discrimination thresholds in Parkinson's disease: results obtained with a rapid computer-controlled colour vision test. Vision Res. 1998;38(21):3427–3431
  13. Müller T, Benz S. Quantification of the dopaminergic response in Parkinson's disease. Parkinsonism Relat. Disord. 2002;8(1):181–186
  14. Müller T, Benz S, Przuntek H. Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients. Can. J. Neurol. Sci. 2002;29(1):73–77
  15. Buddenberg LA, Davis C. Test–retest reliability of the purdue pegboard test. Am. J. Occup. Ther. 2000;54(5):555–558
  16. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann. Neurol. 1997;41(1):58–64
  17. Müller T, Schafer S, Kuhn W, Przuntek H. Correlation between tapping and inserting of pegs in Parkinson's disease. Can. J. Neurol. Sci. 2000;27(4):311–315
  18. Büttner T, Kuhn W, Patzold T, Przuntek H. l-Dopa improves colour vision in Parkinson's disease. J. Neural Transm. Parkinson's Dis. Dementia Sect. 1994;7(1):13–19
  19. Büttner T, Müller T, Kuhn W. Effects of apomorphine on visual functions in Parkinson's disease. J. Neural Transm. 2000;107(1):87–94
  20. Hutton JT, Morris JL, Elias JW. Levodopa improves spatial contrast sensitivity in Parkinson's disease. Arch. Neurol. 1993;50(7):721–724
  21. Nutt JG, Lea ES, Van Houten L, Schuff RA, Sexton GJ. Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: differing effects of brief and continued practice. Mov. Disord. 2000;15(5):843–849
  22. Soliveri P, Brown RG, Jahanshahi M, Marsden CD. Effect of practice on performance of a skilled motor task in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 1992;55(6):454–460
  23. Haug BA, Kolle RU, Trenkwalder C, Oertel WH, Paulus W. Predominant affection of the blue cone pathway in Parkinson's disease. Brain. 1995;118(Pt. 3):771–778
  24. Sandberg MA, Berson EL. Blue and green cone mechanisms in retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 1977;16(2):149–157
  25. Hood DC, Benimoff NI, Greenstein VC. The response range of the blue-cone pathways: a source of vulnerability to disease. Invest. Ophthalmol. Vis. Sci. 1984;25(7):864–867
  26. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci. 1990;13(7):296–302
  27. Dacey DM. The dopaminergic amacrine cell. J. Comp. Neurol. 1990;301(3):461–489
  28. Ehinger B. Connections between retinal neurons with identified neurotransmitters. Vision Res. 1983;23(11):1281–1291
  29. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J. Neurol. 1997;244(1):2–8
  30. Brown RG, Marsden CD. Internal versus external cues and the control of attention in Parkinson's disease. Brain. 1988;111(Pt. 2):323–345
  31. Brown RG, Marsden CD. Dual task performance and processing resources in normal subjects and patients with Parkinson's disease. Brain. 1991;114(Pt. 1A):215–231
  32. Claus JJ, Mohr E. Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases. Acta Neurol. Scand. 1996;93(5):346–351
  33. Meco G, Gasparini M, Doricchi F. Attentional functions in multiple system atrophy and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 1996;60(4):393–398
  34. Dunnewold RJ, Jacobi CE, van Hilten JJ. Quantitative assessment of bradykinesia in patients with Parkinson's disease. J. Neurosci. Methods. 1997;74(1):107–112
  35. Lalonde R, Botez-Marquard T. The neurobiological basis of movement initiation. Rev. Neurosci. 1997;8(1):35–54
  36. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J. New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. J. Neural Transm. 1996;48:1–6 (Suppl.)
  37. Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN. Nigral and extranigral pathology in Parkinson's disease. J. Neural Transm. 1995;46:15–31 (Suppl.)

PII: S0022-510X(03)00150-3

doi: 10.1016/S0022-510X(03)00150-3

Journal of the Neurological Sciences
Volume 213, Issue 1 , Pages 61-65 , 15 September 2003

Article Tools

* Image Usage & Resolution